NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: INDSWFTLAB · data 2026-10-31
Ind-Swift Laboratories Ltd.
In plain words
Price: 13.7% below its 52-week high of ₹426.6.
Delivery: 45.8% of traded shares were kept for delivery over the last 10 sessions, against 39.9% over the last 60.
Latest results: a net profit of ₹0 cr for the quarter ended Dec 2024.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹753 cr |
| Net profit (last 12 months) | ₹84 cr |
| Sales growth, 3 years (yearly) | -19.6% |
| Profit growth, 3 years (yearly) | -3.2% |
At a glance
Promoters 42.9% (+3.4 pts in a year), pledged 0.0%, institutions 11.0%.
P/E 38.1, P/B 2.2, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 3.4%, ROCE -0.2%, operating margin 9.4%: how much profit it earns on the money it uses.
Debt/equity 0.01, Profit growth -3.2% and sales growth -19.6% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- Promoters raised their holding by 3.4 points in a year.
- Low return on equity (3.4%).
- Profit fell 3.2% a year over 3 years.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q3 FY25)
INDSWFTLAB Q3 FY25 results (consolidated figures, as filed on NSE).
Revenue was ₹8.66 crore, down 27.6% QoQ.
Net profit was ₹0.01 crore, down 97.6% QoQ.
Operating margin was 167.7%.
EPS was ₹0, down 100% QoQ.
INDSWFTLAB के Q3 FY25 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹8.66 करोड़; पिछली तिमाही की तुलना में 27.6% की गिरावट।
शुद्ध मुनाफ़ा: ₹0.01 करोड़; पिछली तिमाही की तुलना में 97.6% की गिरावट।
ऑपरेटिंग मार्जिन: 167.7%।
EPS: ₹0; पिछली तिमाही की तुलना में 100% की गिरावट।
INDSWFTLABના Q3 FY25 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹8.66 કરોડ; ગયા ક્વાર્ટરની સરખામણીએ 27.6% ઘટાડો.
ચોખ્ખો નફો: ₹0.01 કરોડ; ગયા ક્વાર્ટરની સરખામણીએ 97.6% ઘટાડો.
ઓપરેટિંગ માર્જિન: 167.7%.
EPS: ₹0; ગયા ક્વાર્ટરની સરખામણીએ 100% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
24/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 10/30: Delivery 40.1% over the last 20 sessions vs 27.4% in the 40 before (1.46x); shares delivered per day 0.77x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 9/15: 0 insider buy days (promoter group among them) and 2 SAST acquisition days in 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Insider ● Results
- 28 Oct 26Insider SAST disclosure: Essix Biosciences Limited acquired 14,00,000 shares +11.1% next session
- 28 Sept 26Insider SAST disclosure: Essix Biosciences Limited acquired shares +2.2% next session
- 10 Aug 26Results Results board meeting +24.6% next session
- 28 May 26Results Results board meeting +12.8% next session
- 31 Jan 26Results Results board meeting -0.6% next session
- 14 Nov 25Results Results board meeting -3.7% next session
- 13 Aug 25Results Results board meeting -2.6% next session
- 30 May 25Results Results board meeting +3.3% next session
- 14 Feb 25Results Q3 FY25 results: net profit ₹0 cr +4.0% next session
- 12 Nov 24Results Q2 FY25 results: net profit ₹0.4 cr -2.9% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Dec 2024 | ₹9 cr | ₹0 cr | — | -167.7% | 0 |
| Sept 2024 | ₹12 cr | ₹0 cr | — | -98.6% | 0.07 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 42.93% | 42.93% | 42.99% | 39.50% |
| Foreign institutions (FII) | 10.78% | 10.70% | 13.88% | 14.33% |
| Domestic institutions (DII) | 0.20% | 0.17% | 0.00% | 0.68% |
| Mutual funds | 0.00% | 0.00% | 0.00% | 0.00% |
| Retail investors | 13.56% | 13.75% | 13.07% | 15.33% |
| Number of shareholders | 42,667 | 40,881 | 39,222 | 42,121 |
Common questions
What was Ind-Swift Laboratories Ltd.'s latest quarterly profit?
Ind-Swift Laboratories Ltd. reported a net profit of ₹0 cr for the quarter ended Dec 2024, on revenue of ₹9 cr.
How much do promoters hold in Ind-Swift Laboratories Ltd.?
Promoters held 42.93% of Ind-Swift Laboratories Ltd. at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Ind-Swift Laboratories Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.01, which is very low.
What is Ind-Swift Laboratories Ltd.'s P/E ratio?
About 38.2, based on the last 12 months' earnings and a price of ₹368.2 (data 2026-10-31).
What is the 52-week high and low of Ind-Swift Laboratories Ltd.?
The 52-week high is ₹426.6 and the 52-week low is ₹87.15.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Ind-Swift Laboratories Ltd. | ₹368.2 | ₹3,195 cr | 38.2 | 2.2 | 3.4% | -0.2% | 0.01 | +260.3% |
| Kwality Pharmaceuticals Ltd | ₹3,475.3 | ₹3,604 cr | 44.5 | — | 22.6% | 31.4% | 0.39 | +98.9% |
| Unichem Laboratories Limited | ₹483.75 | ₹3,404 cr | 11.2 | — | 9.8% | -0.5% | 0.18 | +3.4% |
| Shukra Pharmaceuticals Ltd. | ₹74.87 | ₹3,295 cr | 96.6 | — | 28.9% | 31.3% | 0.06 | +78.1% |
| Solara Active Pharma Sciences Ltd. | ₹632.6 | ₹3,043 cr | 84.2 | 2.1 | -0.6% | 5.9% | 0.55 | +6.1% |
| Hikal Limited | ₹211.58 | ₹2,601 cr | — | — | -4% | 3.1% | 0.57 | -13.1% |
Compare INDSWFTLAB with KPL in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open INDSWFTLAB in NSE Scanner →